Focus: Hamilton Medical is a Swiss medical device manufacturer specializing in mechanical ventilators for intensive care and respiratory support, serving global hospital networks with mid-sized revenue base.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Hot — 65 jobs added in 30d
Net +50 (65 new, 15 removed). Aggressive expansion phase.
Hamilton Medical offers stability and respiratory-tech credibility, but extreme revenue concentration and poorly tracked R&D pose execution risk; best for device/engineering careers seeking established infrastructure, not drug-development scientists.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Dominant revenue driver (99% of portfolio) but commoditized generic in post-exclusivity phase with minimal Part D spending.
Help build intelligence for Hamilton medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hamilton medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Minor formulation variant with negligible Part D spending, underscores generic compression.
Branded NAPROXEN facing imminent loss of exclusivity with no revenue protection mechanisms.
Additional ANDA formulation in post-LOE phase with no measurable Part D revenue.
Duplicate entry indicating fragmented product management of commodity NSAID.
Additional ANDA with no revenue tracking, further evidence of generic portfolio dilution.
Post-LOE entry with no differentiation or revenue attribution.
Final duplicate ANDA reflecting undifferentiated generic competition.
Redundant portfolio entry with no distinct clinical or commercial profile.
9 discontinued, 9 duplicate formulations not shown
This Week at FDA: Upcoming Senate markup, first OTC CGM for children, and more - RAPS
This Week at FDA: Upcoming Senate markup, first OTC CGM for children, and more RAPS
Early Alert for Hamilton Medical Ventilator Breathing Circuit - respiratory-therapy.com
Early Alert for Hamilton Medical Ventilator Breathing Circuit respiratory-therapy.com
Hamilton Medical Hamilton-C6 ICU Ventilator - respiratory-therapy.com
Hamilton Medical Hamilton-C6 ICU Ventilator respiratory-therapy.com
PTC Expands Hamilton Medical Partnership As AI And Valuation Draw Focus - Yahoo Finance
PTC Expands Hamilton Medical Partnership As AI And Valuation Draw Focus Yahoo Finance
Hamilton Medical selects PTC Codebeamer ALM - Medical Design & Outsourcing
Hamilton Medical selects PTC Codebeamer ALM Medical Design & Outsourcing
PTC Codebeamer Replaces Legacy System at Hamilton Medical - PR Newswire
PTC Codebeamer Replaces Legacy System at Hamilton Medical PR Newswire
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Early changes of lung mechanics after positive end-expiratory pressure reduction in acute respiratory distress syndrome: a four-dimensional computed tomography study.
Pre-emptive and Prophylactic Strategies to Prevent Cardiovascular and Neurotoxicity in Chimeric Antigen Receptor T-Cell Therapy: The Role of Tocilizumab, Anakinra, and Cytokine-Targeted Interventions.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo